Erschienen in:
01.06.2015 | Letter
Within-class differences of the sulfonylureas should be accounted for. Reply to Schrijnders D, Kleefstra N and Landman GWD [letter]
verfasst von:
Jonathan C. Levy, Axel Riefflin, Rury R. Holman
Erschienen in:
Diabetologia
|
Ausgabe 6/2015
Einloggen, um Zugang zu erhalten
Excerpt
To the Editor: Schrijnders et al [
1] express concern that the findings of our paper [
2], highlighting the continued enhancement of insulin secretion by glibenclamide at near-normal glucose levels, may have been unduly extrapolated to other drugs in the sulfonylurea class. Whilst we emphasised (correctly in our view) in the discussion ‘the need for cautious titration when using sulfonylureas as second-line agents after metformin when attempting to maintain tight glucose control’, our abstract conclusion was specific to glibenclamide stating: ‘This study highlights the risks of hypoglycaemia when aiming for tight glucose control on this agent.’ …